Chitosan Hydrogel Incorporated with Bone Marrow Mesenchymal Stem Cell-derived Exosomal TIMP2 to Inhibit Angiogenesis in Cholangiocarcinoma DOI
Fei Song, Dan Xu,

Jiayin Che

et al.

Tissue and Cell, Journal Year: 2024, Volume and Issue: 93, P. 102694 - 102694

Published: Dec. 18, 2024

Language: Английский

Hemostatic and antimicrobial properties of chitosan-based wound healing dressings: A review DOI

Jieyu Su,

Chengsheng Liu, Ao Sun

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 306, P. 141570 - 141570

Published: Feb. 27, 2025

Language: Английский

Citations

1
Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis DOI Creative Commons

Zhonghua Zhao,

Xiongying Jiang,

Shiping Wen

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 7, 2025

The present work focused on assessing whether hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab was safe effective advanced hepatocellular carcinoma (HCC) showing high tumor burden. In the multicenter retrospective study, treatment-naive HCC patients (BCLC stage C) burden (maximum diameter of intrahepatic lesion beyond 7 cm) treated or without HAIC were reviewed for eligibility from June 2020 to 2023. Baseline differences between groups mitigated by propensity score matching (PSM). Our primary endpoint overall survival (OS); secondary endpoints included adverse events (AEs), progression-free (PFS), disease control rate (DCR) objective response (ORR) according RECIST 1.1 criteria, respectively. After reviewed, total 162 enrolled: 63 (HTP group), remaining 99 (TP group). PSM 1:1, 47 cases evenly divided into each group. Of them, HTP group showed significant prolonged median OS compared TP (16.6 versus 21.0 months; hazard ratio [HR]: 0.26, 95% confidence interval [CI]: 0.35-0.98; p = 0.039), PFS also (8.9 11.6 HR: 0.55, CI: 0.34-0.87; 0.010). Higher DCR ORR could be observed in relative (ORR: 53.2% 17.0%, < 0.001; DCR: 87.2% 61.7%, 0.004). severe AEs (grade 3/4) all grades comparable groups, while these controlled, grade 5 not reported. is candidate treatment because its improved prognosis acceptable safety.

Language: Английский

Citations

0
Synthesis, characterization and computational study of chitosan-modified pH-responsive Mag@ZIF-8/CS drug delivery system loaded with magnolol for sustained drug release and synergistic antibacterial activity DOI
Safdar Ali Amur,

Quratulain Khuhro,

Najaf Ali Soomro

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 142144 - 142144

Published: March 1, 2025

Language: Английский

Citations

0
Targeting drug cocktail hydrogel platform for inhibiting tumor growth and metastasis DOI Creative Commons

Liying Xiao,

Jiawen Hou,

Hongxiang Liu

et al.

Materials Today Bio, Journal Year: 2025, Volume and Issue: unknown, P. 101798 - 101798

Published: April 1, 2025

Language: Английский

Citations

0
Chitosan Hydrogel Incorporated with Bone Marrow Mesenchymal Stem Cell-derived Exosomal TIMP2 to Inhibit Angiogenesis in Cholangiocarcinoma DOI
Fei Song, Dan Xu,

Jiayin Che

et al.

Tissue and Cell, Journal Year: 2024, Volume and Issue: 93, P. 102694 - 102694

Published: Dec. 18, 2024

Language: Английский

Citations

0